162
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Ketamine and GHB: new trends in club drug use?

&
Pages 11-15 | Published online: 12 Jul 2009
 

Abstract

Around the world the use of ecstasy and other party drugs appears to be increasing. LSD, amphetamines and cocaine, together with ecstasy and its derivatives, have been a part of the Australian dance party/nightclub scene for some time. In recent years, drugs such as ketamine ('Special K') and gammahydroxybutyrate (GHB) have also begun to become popular with some sections of the dance community. Ketamine was developed as a short-acting general anaesthetic for human and veterinary use. Little is known about the illicit use of the drug but a study examining 100 illicit ketamine users found they may experience temporary paralysis, confusion and lack of awareness of time. GHB first appeared in Australia in 1996 when a number of patrons collapsed outside a nightclub after taking what was then called 'fantasy'. The street name of the drug has changed many times since, to names such as 'liquid ecstasy' and 'liquid E'. Over 200 people overdosed on GHB in Sydney in a two-month period in 1997, and GHB has caused significant problems for venues and dance party promoters. This paper examines the history of these drugs and their effects. The authors also suggest some possible harm reduction messages for GHB and ketamine users.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.